<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000648590">
  <TermName>fosaprepitant dimeglumine</TermName>
  <TermPronunciation>(FOS-uh-PREH-pih-tunt dy-MEG-loo-meen)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A drug used together with other drugs to prevent and control nausea and vomiting caused by cancer treatment. It is given in a vein. It is a type of antiemetic and a type of substance P/neurokinin 1 receptor antagonist. Also called Emend for Injection.</DefinitionText>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000725682" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;fosaprepitant dimeglumine&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000725681" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;fosaprepitant dimeglumina&quot;" language="es" id="_4"/>
  <SpanishTermName>fosaprepitant dimeglumina</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Medicamento que se usa junto con otros medicamentos para prevenir y controlar las náuseas y los vómitos causados por el tratamiento de cáncer. Se administra a través de una vena. Es un tipo de antiemético y de antagonista del receptor de neurocinina-1 y sustancia P. También se llama Emend por inyección.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2010-01-11</DateFirstPublished>
</GlossaryTerm>
